Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
News|Videos|July 27, 2023
Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC
Author(s)Solange Peters, MD, PhD
Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.
Advertisement
Solange Peters, MD, PhD, full professor, chair, Medical Oncology, Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5